10 Results for "

HSD17B13-IN-17

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "HSD17B13-IN-17" in MCE Product Catalog:

Cat. No.: HY-161218
CAS No.: 2758802-10-5
Target:  

17β-HSD

Research Areas:  

Metabolic Disease

HSD17B13-IN-17 (compound 9) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM and? < 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-17? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
loading...
    loading...
Cat. No.: HY-128145
CAS No.: 1122660-25-6
Target:  

17β-HSD

Research Areas:  

Metabolic Disease

HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
loading...
    loading...
Cat. No.: HY-179015
Target:  

17β-HSD PPAR

HSD17B13/PPAR modulator-1 (Compound 17) is a HSD17B13/PPAR multitarget modulator. HSD17B13/PPAR modulator-1 is an inhibitor of HSD17B13, with its IC50 value being 0.91 μM. HSD17B13/PPAR modulator-1 is a PPAR agonist, with the EC50 values for PPARα, PPARδ, and PPARγ being 1.55, 0.12, and 0.01 μM respectively. HSD17B13/PPAR modulator-1 can significantly improve liver function, regulate lipid metabolism, alleviate fibrosis, and exert antioxidant and anti-inflammatory effects in the model of metabolic dysfunction-related steatohepatitis (MASH). HSD17B13/PPAR modulator-1 can be used for the study of MASH .
loading...
    loading...
Cat. No.: HY-172122
CAS No.: 3067566-36-0
Target:  

FXR 17β-HSD

Research Areas:  

Metabolic Disease

FXR/HSD17B13 modulator 1 (compound 6) is a potent modulator of FXR/HSD17B13. FXR/HSD17B13 modulator 1 plays an important roel in metabolic dysfunction-associated steatohepatitis (MASH) research .
loading...
    loading...
Cat. No.: HY-157664
CAS No.: 2730022-56-5
Target:  

17β-HSD

Research Areas:  

Metabolic Disease

HSD17B13-IN-38 (Compound D) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
loading...
    loading...
Cat. No.: HY-157665
CAS No.: 2730022-55-4
Target:  

17β-HSD

Research Areas:  

Metabolic Disease

HSD17B13-IN-39 (Compound A) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-39 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
loading...
    loading...
Cat. No.: HY-157650
CAS No.: 2919797-59-2
Target:  

17β-HSD

Research Areas:  

Metabolic Disease

HSD17B13-IN-38 (Compound 18.02) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-157653
CAS No.: 2919797-60-5
Target:  

17β-HSD

Research Areas:  

Metabolic Disease

HSD17B13-IN-22 (Compound 18.03) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-22 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-157654
CAS No.: 2919797-61-6
Target:  

17β-HSD

Research Areas:  

Metabolic Disease

HSD17B13-IN-26 (Compound 18.04) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-26 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-183309
Target:  

FXR 17β-HSD

Research Areas:  

Inflammation/Immunology

FXR/HSD17B13-modulator-2 is a dual FXR activator and HSD17B13 inhibitor with human FXR EC50 of 128 nM, human HSD17B13 IC50 of 0.18 μM, high selectivity over related nuclear receptors and HSD17B isoforms, and oral effectiveness.FXR/HSD17B13-modulator-2 alleviates fatty liver, regulates lipid metabolism, reduces inflammation, and attenuates hepatic fibrosis.FXR/HSD17B13-modulator-2 is the first non-carboxylic acid dual FXR/HSD17B13 modulator.FXR/HSD17B13-modulator-2 can be used for the research of metabolic dysfunction-associated steatohepatitis .
loading...
    loading...